Cargando…

Advances in prostate cancer imaging

Many exciting advances in medical imaging have been made in recent years that will alter the way we diagnose, stage, and treat patients with prostate cancer. Multiparametric magnetic resonance imaging (MRI) is emerging as the main modality for prostate cancer imaging. Contrast-enhanced ultrasound an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tangel, Matthew R., Rastinehad, Ardeshir R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113878/
https://www.ncbi.nlm.nih.gov/pubmed/30467517
http://dx.doi.org/10.12688/f1000research.14498.1
_version_ 1783351093593374720
author Tangel, Matthew R.
Rastinehad, Ardeshir R.
author_facet Tangel, Matthew R.
Rastinehad, Ardeshir R.
author_sort Tangel, Matthew R.
collection PubMed
description Many exciting advances in medical imaging have been made in recent years that will alter the way we diagnose, stage, and treat patients with prostate cancer. Multiparametric magnetic resonance imaging (MRI) is emerging as the main modality for prostate cancer imaging. Contrast-enhanced ultrasound and shear wave elastography may be strong alternatives in patients who cannot undergo MRI. Prostate-specific membrane antigen-directed positron emission tomography/computed tomography has proven to be valuable in the primary staging of high-risk disease and for detecting disease in patients with biochemical recurrence. As more studies continue to emerge, it is becoming clear that the standard algorithm for diagnosing and staging prostate cancer will undergo significant changes in the near future.
format Online
Article
Text
id pubmed-6113878
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-61138782018-11-21 Advances in prostate cancer imaging Tangel, Matthew R. Rastinehad, Ardeshir R. F1000Res Review Many exciting advances in medical imaging have been made in recent years that will alter the way we diagnose, stage, and treat patients with prostate cancer. Multiparametric magnetic resonance imaging (MRI) is emerging as the main modality for prostate cancer imaging. Contrast-enhanced ultrasound and shear wave elastography may be strong alternatives in patients who cannot undergo MRI. Prostate-specific membrane antigen-directed positron emission tomography/computed tomography has proven to be valuable in the primary staging of high-risk disease and for detecting disease in patients with biochemical recurrence. As more studies continue to emerge, it is becoming clear that the standard algorithm for diagnosing and staging prostate cancer will undergo significant changes in the near future. F1000 Research Limited 2018-08-24 /pmc/articles/PMC6113878/ /pubmed/30467517 http://dx.doi.org/10.12688/f1000research.14498.1 Text en Copyright: © 2018 Tangel MR and Rastinehad AR http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Tangel, Matthew R.
Rastinehad, Ardeshir R.
Advances in prostate cancer imaging
title Advances in prostate cancer imaging
title_full Advances in prostate cancer imaging
title_fullStr Advances in prostate cancer imaging
title_full_unstemmed Advances in prostate cancer imaging
title_short Advances in prostate cancer imaging
title_sort advances in prostate cancer imaging
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113878/
https://www.ncbi.nlm.nih.gov/pubmed/30467517
http://dx.doi.org/10.12688/f1000research.14498.1
work_keys_str_mv AT tangelmatthewr advancesinprostatecancerimaging
AT rastinehadardeshirr advancesinprostatecancerimaging